https://de.marketscreener.com/kurs/aktie/BASILEA-PHARMACEUTICA-AG-130199/news/Basilea-Pharmaceutica-startet-klinische-Phase-3-Studie-mit-Antibiotikum-Ceftobiprol-bei-Staphyloco-27083657/?utm_source=telegram&utm_medium=social&utm_campaign=share